BioXcel Therapeutics (BTAI) Competitors

$1.07 -0.04 (-3.17%)

Closing price 06/9/2026 04:00 PM Eastern

Extended Trading

$1.10 +0.03 (+3.27%)

As of 07:09 AM Eastern

BTAI vs. CNTB, IFRX, GNLX, CRDL, and VTVT

Should you buy BioXcel Therapeutics stock or one of its competitors? MarketBeat compares BioXcel Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioXcel Therapeutics include Connect Biopharma (CNTB), InflaRx (IFRX), Genelux (GNLX), Cardiol Therapeutics (CRDL), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.

How does BioXcel Therapeutics compare to Connect Biopharma?

BioXcel Therapeutics (NASDAQ:BTAI) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

BioXcel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 928.04%. Connect Biopharma has a consensus target price of $7.20, suggesting a potential upside of 239.62%. Given BioXcel Therapeutics' higher probable upside, equities analysts clearly believe BioXcel Therapeutics is more favorable than Connect Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Connect Biopharma has lower revenue, but higher earnings than BioXcel Therapeutics. Connect Biopharma is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	51.63	-$69.90M	-$5.75	N/A
Connect Biopharma	$60K	2,224.59	-$55.48M	-$1.15	N/A

Connect Biopharma has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Connect Biopharma	N/A	-122.29%	-97.07%

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BioXcel Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, indicating that its share price is 122% less volatile than the broader market.

In the previous week, BioXcel Therapeutics and BioXcel Therapeutics both had 1 articles in the media. Connect Biopharma's average media sentiment score of 1.91 beat BioXcel Therapeutics' score of 1.43 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Positive
Connect Biopharma	Very Positive

Summary

Connect Biopharma beats BioXcel Therapeutics on 11 of the 16 factors compared between the two stocks.

How does BioXcel Therapeutics compare to InflaRx?

BioXcel Therapeutics (NASDAQ:BTAI) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

InflaRx has lower revenue, but higher earnings than BioXcel Therapeutics. InflaRx is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	51.63	-$69.90M	-$5.75	N/A
InflaRx	$30K	4,000.05	-$51.63M	-$0.71	N/A

InflaRx has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
InflaRx	N/A	-88.30%	-65.77%

In the previous week, BioXcel Therapeutics and BioXcel Therapeutics both had 1 articles in the media. InflaRx's average media sentiment score of 1.89 beat BioXcel Therapeutics' score of 1.43 indicating that InflaRx is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Positive
InflaRx	Very Positive

BioXcel Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, InflaRx has a beta of 2.42, meaning that its stock price is 142% more volatile than the broader market.

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 42.4% of InflaRx shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 16.3% of InflaRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

BioXcel Therapeutics presently has a consensus price target of $11.00, indicating a potential upside of 928.04%. InflaRx has a consensus price target of $7.00, indicating a potential upside of 321.69%. Given BioXcel Therapeutics' higher possible upside, equities analysts plainly believe BioXcel Therapeutics is more favorable than InflaRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

InflaRx beats BioXcel Therapeutics on 12 of the 16 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Genelux?

Genelux (NASDAQ:GNLX) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

In the previous week, Genelux had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 2 mentions for Genelux and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.43 beat Genelux's score of 0.43 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Genelux	Neutral
BioXcel Therapeutics	Positive

37.3% of Genelux shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genelux has higher earnings, but lower revenue than BioXcel Therapeutics. Genelux is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,362.32	-$32.15M	-$0.85	N/A
BioXcel Therapeutics	$640K	51.63	-$69.90M	-$5.75	N/A

Genelux presently has a consensus target price of $18.00, indicating a potential upside of 504.03%. BioXcel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 928.04%. Given BioXcel Therapeutics' higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Genelux has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Genelux has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

Summary

Genelux beats BioXcel Therapeutics on 11 of the 16 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Cardiol Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

BioXcel Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

BioXcel Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 928.04%. Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 687.04%. Given BioXcel Therapeutics' higher possible upside, equities research analysts plainly believe BioXcel Therapeutics is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, BioXcel Therapeutics and BioXcel Therapeutics both had 1 articles in the media. Cardiol Therapeutics' average media sentiment score of 1.89 beat BioXcel Therapeutics' score of 1.43 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioXcel Therapeutics	Positive
Cardiol Therapeutics	Very Positive

Cardiol Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Cardiol Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	51.63	-$69.90M	-$5.75	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Summary

Cardiol Therapeutics beats BioXcel Therapeutics on 8 of the 13 factors compared between the two stocks.

How does BioXcel Therapeutics compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

vTv Therapeutics has higher revenue and earnings than BioXcel Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	122.72	-$26.97M	-$0.93	N/A
BioXcel Therapeutics	$640K	51.63	-$69.90M	-$5.75	N/A

vTv Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. vTv Therapeutics' return on equity of 3.96% beat BioXcel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

vTv Therapeutics presently has a consensus price target of $53.00, suggesting a potential upside of 66.82%. BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 928.04%. Given BioXcel Therapeutics' higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

vTv Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

In the previous week, vTv Therapeutics had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.43 beat vTv Therapeutics' score of 0.62 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
vTv Therapeutics	Positive
BioXcel Therapeutics	Positive

Summary

vTv Therapeutics beats BioXcel Therapeutics on 12 of the 17 factors compared between the two stocks.

Get BioXcel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTAI vs. The Competition

Export

Metric	BioXcel Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$34.12M	$3.30B	$6.64B	$12.06B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-0.19	18.68	24.50	23.76
Price / Sales	51.63	297.55	503.68	105.22
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	-0.24	8.06	10.36	6.72
Net Income	-$69.90M	$23.83M	$3.56B	$337.35M
7 Day Performance	-7.76%	-2.51%	-1.01%	-1.21%
1 Month Performance	-12.30%	2.22%	1.21%	1.41%
1 Year Performance	-46.23%	36.40%	20.40%	23.64%

BioXcel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTAI BioXcel Therapeutics	2.7568 of 5 stars	$1.07 -3.2%	$11.00 +928.0%	-45.4%	$34.12M	$640K	N/A	90	Positive News
CNTB Connect Biopharma	3.9658 of 5 stars	$2.18 -5.2%	$7.20 +230.3%	+171.4%	$137.26M	$233K	N/A	110	Positive News
IFRX InflaRx	2.8952 of 5 stars	$1.86 -7.3%	$7.00 +277.4%	+95.3%	$134.10M	$29.33K	N/A	60	Positive News
GNLX Genelux	2.0089 of 5 stars	$2.94 -4.6%	$18.00 +512.7%	+10.0%	$131.52M	$10K	N/A	10
CRDL Cardiol Therapeutics	2.5443 of 5 stars	$1.13 -2.2%	$8.50 +655.6%	-25.0%	$129.66M	N/A	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTAI) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. CNTB, IFRX, GNLX, CRDL, and VTVT

How does BioXcel Therapeutics compare to Connect Biopharma?

Summary

How does BioXcel Therapeutics compare to InflaRx?

Summary

How does BioXcel Therapeutics compare to Genelux?

Summary

How does BioXcel Therapeutics compare to Cardiol Therapeutics?

Summary

How does BioXcel Therapeutics compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. CNTB, IFRX, GNLX, CRDL, and VTVT

How does BioXcel Therapeutics compare to Connect Biopharma?

Do analysts prefer BTAI or CNTB?

Which has preferable earnings and valuation, BTAI or CNTB?

Is BTAI or CNTB more profitable?

Do insiders & institutionals hold more shares of BTAI or CNTB?

Which has more risk & volatility, BTAI or CNTB?

Does the media prefer BTAI or CNTB?

Summary

How does BioXcel Therapeutics compare to InflaRx?

Which has higher earnings and valuation, BTAI or IFRX?

Is BTAI or IFRX more profitable?

Does the media prefer BTAI or IFRX?

Which has more volatility and risk, BTAI or IFRX?

Do institutionals and insiders have more ownership in BTAI or IFRX?

Do analysts recommend BTAI or IFRX?

Summary

How does BioXcel Therapeutics compare to Genelux?

Does the media favor GNLX or BTAI?

Do institutionals & insiders have more ownership in GNLX or BTAI?

Which has stronger valuation and earnings, GNLX or BTAI?

Do analysts rate GNLX or BTAI?

Which has more volatility & risk, GNLX or BTAI?

Is GNLX or BTAI more profitable?

Summary

How does BioXcel Therapeutics compare to Cardiol Therapeutics?

Which has more volatility and risk, BTAI or CRDL?

Do analysts rate BTAI or CRDL?

Do institutionals & insiders believe in BTAI or CRDL?

Does the media prefer BTAI or CRDL?

Is BTAI or CRDL more profitable?

Which has preferable earnings and valuation, BTAI or CRDL?

Summary

How does BioXcel Therapeutics compare to vTv Therapeutics?

Which has stronger earnings & valuation, VTVT or BTAI?

Is VTVT or BTAI more profitable?

Do analysts prefer VTVT or BTAI?

Do insiders & institutionals hold more shares of VTVT or BTAI?

Which has more risk & volatility, VTVT or BTAI?

Does the media prefer VTVT or BTAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools